Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the innovative biopharmaceutical injectable BL-M05D1 (Claudin18.2 ADC) program for CLDN18.2 positive advanced gastric cancer or gastroesophageal adenocarcinoma (GC/GEJC) patients who have previously been treated with first-line standards has been included in the list of breakthrough treatments by the Drug Evaluation Center of the State Drug Administration (“Drug Evaluation Center”).

Zhitongcaijing · 1d ago
Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the innovative biopharmaceutical injectable BL-M05D1 (Claudin18.2 ADC) program for CLDN18.2 positive advanced gastric cancer or gastroesophageal adenocarcinoma (GC/GEJC) patients who have previously been treated with first-line standards has been included in the list of breakthrough treatments by the Drug Evaluation Center of the State Drug Administration (“Drug Evaluation Center”).